Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

Florou, Vaia; Rosenberg, Andrew E.; Wieder, Eric; Komanduri, Krishna V.; Kolonias, Despina; Uduman, Mohamed; Castle, John C.; Buell, Jennifer S.; Trent, Jonathan C.; Wilky, Breelyn A.

doi:10.1186/s40425-019-0689-7

Table 1 Patient demographics and characteristics. cAS cutaneous angiosarcoma, RAS radiation associated angiosarcoma

From: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

Patient	Demographics	Pathology	Disease state	Prior therapies	Immunotherapy	Number of ICI doses	Response at 12 weeks	Duration of response to ICI	Best Overall Response	Post ICI therapies
1	32-year-old female	Primary breast AS	MetastaticSoft tissue, Bones	Gemcitabine/ Docetaxel	Axitinib + Pembrolizumab (NCT02636725)	4	Progression of disease		Progression of disease	Paclitaxel Doxorubicin/ Olaratumab
2	71-year-old female	Breast RAS	Metastatic Mediastinal lymph nodes, Lung	Doxorubicin/ Olaratumab, Gemcitabine/ Docetaxel, Pazopanib	Pembrolizumab	5	Partial response	Ongoing	Partial response	N/A
3	62-year-old female	cAS	Locally advanced- face	Doxorubicin, Gemcitabine/ Docetaxel, Pazopanib, Ifosfamide, Notch Inhibitor (NCT01695005), Temozolamide/ Bevacizumab	Anti-CTLA-4 (NCT02694822)	14	Partial response	Ongoing	Complete response	None
4	68-year-old female	cAS	Metastatic Lymph nodes, Bones	IL-2/ Cyclophosphamide/ Methotrexate, Paclitaxel, Bevacizumab	Pembrolizumab	6	Partial response^b	14 weeks	Partial response^b	N/A
4	68-year-old female	cAS	Metastatic Lymph nodes, Bones		Ipilimumab/Nivolumab	8	Partial response^b	Ongoing	Partial response^b	N/A
5	89-year-old female	cAS	Multifocal- scalp	Gemcitabine, Paclitaxel, Pazopanib	Pembrolizumab	5	Partial response^a	Ongoing	Partial response	None
6	76-year-old male	cAS	Multifocal- scalp	Pazopanib/TRC105 (NCT02979899), Doxorubicin/ Cyclophosphamide/ Olaratumab, Gemcitabine/ Docetaxel	Pembrolizumab	5	Partial response^a	Ongoing	Partial response	N/A
7	65-year-old male	cAS	Multifocal- nose	Doxorubicin/ Ifosfamide, Doxorubicin/ Cyclophosphamide, Gemcitabine/ Docetaxel	Anti-CTLA-4 (NCT02694822)	7	Progression of disease		Progression of disease	Pazopanib

^aResponse assessed by clinical exam only ^bResponse assessed by clinical exam and imaging

Back to article page